Tiny Redx slammed after first patient is hit by adverse events, forcing a halt to cancer drug study
The microcap biotech Redx has lurched from a financial pickle straight into a damaging safety issue with its lead drug.
The UK biotech has suspended a Phase I/II trial after the first patient dosed experienced serious adverse events that were “possibly related to RXC004 on-target effects and Wnt pathway inhibition. Importantly, analysis of data from this first patient indicates that their systemic RXC004 exposure was significantly higher than that predicted from preclinical studies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.